Chemistry:Erteberel
 | |
| Clinical data | |
|---|---|
| Other names | Selective estrogen receptor beta agonist-1; SERBA-1; LY-500307; (3aS,4R,9bR)-1,2,3,3a,4,9b-Hexahydro-4-(4-hydroxyphenyl)cyclopenta(c)(1)benzopyran-8-ol; (2R,3S,4R)-SERBA[1] |
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C18H18O3 |
| Molar mass | 282.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Erteberel (INN, USAN; former developmental code name LY-500307; also known as selective estrogen receptor beta agonist-1 or SERBA-1) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and is under development by Eli Lilly for the treatment of schizophrenia.[2][3][4] It is specifically under investigation for the treatment of negative symptoms and cognitive impairment associated with the condition.[2] As of 2015, it is in phase II clinical trials for this indication in the United States .[2] Erteberel was also under investigation for the treatment of benign prostatic hyperplasia and reached phase II clinical studies for this use but failed to improve symptoms in men with the condition and development for this indication was discontinued.[2][5] The drug has also been proposed as a potential novel treatment for glioblastoma.[6]
Erteberel has 14-fold binding selectivity for the ERβ over the ERα (Ki = 0.19 nM versus 2.68 nM, respectively).[3][7] However, it shows 32-fold functional selectivity for activation of the ERβ over the ERα (EC50 = 0.66 nM versus 19.4 nM, respectively).[7] It is roughly a full agonist of both the ERβ and ERα (Emax = 101% versus 94%, respectively).[3][7] Although selective for the ERβ, erteberel loses its selectivity at high dosages and activates the ERα as well, producing effects such as suppression of gonadal testosterone production in men.[8]
See also
- List of investigational sex-hormonal agents § Estrogenics
- List of investigational antipsychotics
- Estrogen receptor beta § Agonists
References
- ↑ "Estrogen receptor ligands: a patent review update". Expert Opin Ther Pat 23 (10): 1247–71. 2013. doi:10.1517/13543776.2013.805206. PMID 23713677.
- ↑ 2.0 2.1 2.2 2.3 "Erteberel - AdisInsight". https://adisinsight.springer.com/drugs/800031986.
- ↑ 3.0 3.1 3.2 "Estrogen receptor β ligands: recent advances and biomedical applications". Med Res Rev 31 (3): 364–442. 2011. doi:10.1002/med.20186. PMID 19967775.
- ↑ "Development of subtype-selective oestrogen receptor-based therapeutics". Nat Rev Drug Discov 10 (10): 778–92. 2011. doi:10.1038/nrd3551. PMID 21921919.
- ↑ "Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy". Prostate Cancer Prostatic Dis. 18 (1): 43–8. 2015. doi:10.1038/pcan.2014.43. PMID 25348255.
- ↑ "Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma". Sci Rep 6: 24185. 2016. doi:10.1038/srep24185. PMID 27126081. Bibcode: 2016NatSR...624185S.
- ↑ 7.0 7.1 7.2 "Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia". J. Med. Chem. 49 (21): 6155–7. 2006. doi:10.1021/jm060491j. PMID 17034120.
- ↑ "Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men". Clinical Pharmacology in Drug Development 4 (4): 305–14. 2015. doi:10.1002/cpdd.184. PMID 27136911.
External links
 |  |
